Cargando…
Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver?
BACKGROUND: Telehealth services are rapidly embraced in uro-oncology due to the current coronavirus disease 2019 (COVID-19) pandemic. OBJECTIVE: To determine patients’ perspective on adoption of telehealth as a response to the pandemic and its sustainability in the future. DESIGN, SETTING, AND PARTI...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Association of Urology. Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286644/ https://www.ncbi.nlm.nih.gov/pubmed/32534969 http://dx.doi.org/10.1016/j.euf.2020.05.010 |
_version_ | 1783544909170475008 |
---|---|
author | Rodler, Severin Apfelbeck, Maria Schulz, Gerald Bastian Ivanova, Troya Buchner, Alexander Staehler, Michael Heinemann, Volker Stief, Christian Casuscelli, Jozefina |
author_facet | Rodler, Severin Apfelbeck, Maria Schulz, Gerald Bastian Ivanova, Troya Buchner, Alexander Staehler, Michael Heinemann, Volker Stief, Christian Casuscelli, Jozefina |
author_sort | Rodler, Severin |
collection | PubMed |
description | BACKGROUND: Telehealth services are rapidly embraced in uro-oncology due to the current coronavirus disease 2019 (COVID-19) pandemic. OBJECTIVE: To determine patients’ perspective on adoption of telehealth as a response to the pandemic and its sustainability in the future. DESIGN, SETTING, AND PARTICIPANTS: Following a COVID-19 outbreak, 101 patients with advanced genitourinary cancers are currently managed “virtually” for therapy administration at our tertiary care unit. They were surveyed about the current situation, and current and long-term employment of telehealth. INTERVENTION: Rapid implementation of virtual patient management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients’ perception of anxiety of COVID-19 and cancer, perspective on telehealth measures as a reaction to the current COVID-19 pandemic, and long-term acceptance were used as outcomes. Wilcoxon matched-pair signed rank test, chi-square test, and Mann-Whitney U test were performed. RESULTS AND LIMITATIONS: Of 101 patients, 92 answered the questionnaire, with 71 (77.2%) responding virtually by e-mail or phone call. Anxiety of cancer (6/10, interquartile range [IQR] 3–8) superseded that of COVID-19 (four/10, IQR 2–5.25, p < 0.001), and patients oppose temporary treatment interruption. Of the patients, 66.0% perceive their susceptibility to COVID-19 as equal to or lower than the general population and 52.2% believe that COVID-19 will not affect their therapy. In future, patients (62.6%) prefer to maintain in-person appointments as opposed to complete remote care, but accept remote care during the pandemic (eight/10, IQR 5–9). Beyond the crisis, maintaining telehealth has low preference rates (four/10, IQR 2–7), with high acceptance for external laboratory controls (60.9%) and online visit management (48.9%), but lower acceptance for remote treatment planning including staging discussions (44.6%) and for referral to secondary care oncologists (17.4%). CONCLUSIONS: Despite the pandemic, cancer remains the key concern and patients are not willing to compromise on their treatment. Rapid implementation of telehealth is tolerated well during the need of social distancing, with a clear “red line” concerning changes in existing patient-physician relationships. Balancing future implementation of telehealth while considering patients’ demand for personal relationships will ensure human dignity in uro-oncology. PATIENT SUMMARY: We queried patients with genitourinary cancers treated in an almost virtual setting following a local coronavirus outbreak. Acceptance of telehealth during the current situation is high; however, long-term implementation of the adapted services is less favored. We deduce that patient-physician relationship is crucial for cancer patients and needs to be balanced against measures for social distancing to forge the future management. |
format | Online Article Text |
id | pubmed-7286644 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | European Association of Urology. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72866442020-06-11 Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver? Rodler, Severin Apfelbeck, Maria Schulz, Gerald Bastian Ivanova, Troya Buchner, Alexander Staehler, Michael Heinemann, Volker Stief, Christian Casuscelli, Jozefina Eur Urol Focus Urothelial Cancer BACKGROUND: Telehealth services are rapidly embraced in uro-oncology due to the current coronavirus disease 2019 (COVID-19) pandemic. OBJECTIVE: To determine patients’ perspective on adoption of telehealth as a response to the pandemic and its sustainability in the future. DESIGN, SETTING, AND PARTICIPANTS: Following a COVID-19 outbreak, 101 patients with advanced genitourinary cancers are currently managed “virtually” for therapy administration at our tertiary care unit. They were surveyed about the current situation, and current and long-term employment of telehealth. INTERVENTION: Rapid implementation of virtual patient management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients’ perception of anxiety of COVID-19 and cancer, perspective on telehealth measures as a reaction to the current COVID-19 pandemic, and long-term acceptance were used as outcomes. Wilcoxon matched-pair signed rank test, chi-square test, and Mann-Whitney U test were performed. RESULTS AND LIMITATIONS: Of 101 patients, 92 answered the questionnaire, with 71 (77.2%) responding virtually by e-mail or phone call. Anxiety of cancer (6/10, interquartile range [IQR] 3–8) superseded that of COVID-19 (four/10, IQR 2–5.25, p < 0.001), and patients oppose temporary treatment interruption. Of the patients, 66.0% perceive their susceptibility to COVID-19 as equal to or lower than the general population and 52.2% believe that COVID-19 will not affect their therapy. In future, patients (62.6%) prefer to maintain in-person appointments as opposed to complete remote care, but accept remote care during the pandemic (eight/10, IQR 5–9). Beyond the crisis, maintaining telehealth has low preference rates (four/10, IQR 2–7), with high acceptance for external laboratory controls (60.9%) and online visit management (48.9%), but lower acceptance for remote treatment planning including staging discussions (44.6%) and for referral to secondary care oncologists (17.4%). CONCLUSIONS: Despite the pandemic, cancer remains the key concern and patients are not willing to compromise on their treatment. Rapid implementation of telehealth is tolerated well during the need of social distancing, with a clear “red line” concerning changes in existing patient-physician relationships. Balancing future implementation of telehealth while considering patients’ demand for personal relationships will ensure human dignity in uro-oncology. PATIENT SUMMARY: We queried patients with genitourinary cancers treated in an almost virtual setting following a local coronavirus outbreak. Acceptance of telehealth during the current situation is high; however, long-term implementation of the adapted services is less favored. We deduce that patient-physician relationship is crucial for cancer patients and needs to be balanced against measures for social distancing to forge the future management. European Association of Urology. Published by Elsevier B.V. 2020-09-15 2020-06-10 /pmc/articles/PMC7286644/ /pubmed/32534969 http://dx.doi.org/10.1016/j.euf.2020.05.010 Text en © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Urothelial Cancer Rodler, Severin Apfelbeck, Maria Schulz, Gerald Bastian Ivanova, Troya Buchner, Alexander Staehler, Michael Heinemann, Volker Stief, Christian Casuscelli, Jozefina Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver? |
title | Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver? |
title_full | Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver? |
title_fullStr | Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver? |
title_full_unstemmed | Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver? |
title_short | Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver? |
title_sort | telehealth in uro-oncology beyond the pandemic: toll or lifesaver? |
topic | Urothelial Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286644/ https://www.ncbi.nlm.nih.gov/pubmed/32534969 http://dx.doi.org/10.1016/j.euf.2020.05.010 |
work_keys_str_mv | AT rodlerseverin telehealthinurooncologybeyondthepandemictollorlifesaver AT apfelbeckmaria telehealthinurooncologybeyondthepandemictollorlifesaver AT schulzgeraldbastian telehealthinurooncologybeyondthepandemictollorlifesaver AT ivanovatroya telehealthinurooncologybeyondthepandemictollorlifesaver AT buchneralexander telehealthinurooncologybeyondthepandemictollorlifesaver AT staehlermichael telehealthinurooncologybeyondthepandemictollorlifesaver AT heinemannvolker telehealthinurooncologybeyondthepandemictollorlifesaver AT stiefchristian telehealthinurooncologybeyondthepandemictollorlifesaver AT casuscellijozefina telehealthinurooncologybeyondthepandemictollorlifesaver |